Biotech | January 25, 2022
SQI Diagnostics inks pact with UK-Based Owlstone Medical
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Go-ahead for pivotal clinical trial which is expected to commence by March
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This is the company’s first partnership arrangement in China
Subscribe To Our Newsletter & Stay Updated
